WO2025210592 - MUSCLE CELL LNP-MRNA QUALITY CONTROL ASSAYS
National phase entry is expected:
Publication Number
WO/2025/210592
Publication Date
09.10.2025
International Application No.
PCT/IB2025/053600
International Filing Date
04.04.2025
Title **
[English]
MUSCLE CELL LNP-MRNA QUALITY CONTROL ASSAYS
[French]
DOSAGES DE CONTRÔLE DE QUALITÉ DE LNP-ARNM DE CELLULES MUSCULAIRES
Applicants **
SANOFI PASTEUR INC.
Inventors
ASQUITH, Carla Jane
CHIVUKULA, Sudha
DANZ, Hillary
NOUGARÉDE, Adrien
SHARMA, Shraddha
YOON, Heesik
Priority Data
24315123.0
05.04.2024
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3741 | |
| EPO | Filing, Examination, Granting | 36810 | |
| Japan | Filing, Examination, Granting | 3447 | |
| South Korea | Filing, Examination, Granting | 4710 | |
| USA | Filing, Examination, Granting | 13790 |
Total:
62,498
Contact Us
Abstract[English]
The present disclosure provides an in vitro system comprising a plurality of isolated human muscle cells and a plurality of lipid-nanoparticle (LNP)-encapsulated messenger RNA (mRNA), and methods of screening LNP-encapsulated mRNA for polypeptide expression with said system.[French]
La présente invention concerne un système in vitro comprenant une pluralité de cellules musculaires humaines isolées et une pluralité d'ARN messagers (ARNm) encapsulés dans des nanoparticules lipidiques (LNP), et des procédés de criblage d'ARNm encapsulés dans des LNP pour l'expression polypeptidique avec ledit système.